Carcinoid Heart Disease Clinical Trial
Official title:
Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors Carcinoid Heart Disease (CHD): An Observational French Multi-Centre Cohort Study CRUSOE - NETs (CaRdiac UltraSonic OutcomEs - NETs)
Carcinoid Heart Disease (CHD) is a rare form of heart disease, occurring in over 50% of the
patients with carcinoid syndrome. Pathophysiology, prognostic factors of development of
Carcinoid Heart Disease and progression of disease remain unclear.
This observational multicenter cohort study is designed to study the occurrence of Carcinoid
Heart Disease in patients with differentiated carcinoid tumors, to describe numerous factors
influencing the occurrence, severity, progression and long-term survival of patients with
Carcinoid Heart Disease. Basic informations and detailed diagnosis informations (oncological
and cardiac parameters), are collected by professional doctors. Clinical outcomes (onset of
Carcinoid Heart Disease, cardiac surgery, related death) will be followed up every year or
every six/three months if clinically indicated.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04039516 -
Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT05064514 -
Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
|
N/A | |
| Withdrawn |
NCT04065165 -
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
|
Phase 3 |